It is not typical for a medical device concept in the United States to reach direct use; instead, it typically follows alternative pathways. Feasibility measures constrained by grant cycles, safety data reviewed by people from the very early days, even before human trials, and questions about commercialization arising well before the device is used in patients are among the factors that demonstrate the nonlinearity of the device’s path to use. The example furthest from the direct path is mechanical circulatory support, whose development timelines take decades and have a high failure rate. Ideas funded by federal agencies such as the National Institutes of Health often are the ones that survive long enough to be tested in real clinical settings.
Kurt A. Dasse, Ph.D., against this background, fashioned his career around holding on to one piece of federally funded translational research after another. It is not a single program or role that characterizes his work; rather, repeated principal investigator appointments, long-term participation in NIH Small Business Innovation Research efforts, and contributions to national initiatives such as PUMPKIN, which supports pediatric cardiac device development, are the main elements of his work.
The devices that mechanically support the heart constitute a distinct class of innovation in biomedicine. The costs of development are high, timelines are long, and expectations from regulators are stringent. Initial engineering works are far ahead of potential private investors, especially when patient numbers are low and clinical risks are high. Therefore, NIH grants and contracts are typically the first bridge from the laboratory to the preclinical stage.
Within this framework, the NIH SBIR program plays a specific role. It does not fund discovery science in the traditional sense, nor does it substitute for venture investment. Instead, it supports translational engineering tasks that convert early prototypes into systems capable of surviving regulatory and clinical scrutiny. This includes durability testing, hemocompatibility assessment, preclinical validation, and documentation required for subsequent investigational device exemption applications.
Dasse’s engagement with this funding structure reflects these realities. His NIH-supported projects have focused on mechanical circulatory support devices and related technologies, areas in which private funding alone has historically struggled to sustain early-stage development.
The title of principal investigator carries defined responsibilities beyond authorship or conceptual input. In practice, it requires assembling multidisciplinary teams that integrate engineering, clinical expertise, regulatory planning, and quality systems. A principal investigator must define aims that are technically achievable within fixed funding periods and produce data that can withstand independent review.
In Dasse’s case, this role has included oversight of preclinical studies conducted under GLP-like discipline, coordination with clinical collaborators, and management of data integrity across multi-year programs. Documentation standards remain central, as grant-supported work must align with future regulatory submissions even when clinical trials are not yet underway. These responsibilities emphasize execution rather than visibility, and process rather than immediate outcomes.
Throughout his career, Dasse has served as principal investigator on numerous NIH grants and contracts focused on mechanical circulatory support devices and accessories. The funding totals, as outlined in the provided curriculum materials, reflect a significant contribution to these projects and demonstrate sustained engagement with competitive federal review processes over several years. While funding amounts are not the sole measure of impact, they underscore Dr. Dasse’s continued involvement in advancing these critical technologies.
Projects supported through these mechanisms have typically addressed challenges specific to circulatory support systems. These include infection-reduction strategies, performance of blood-contacting surfaces, mitigation of right-heart failure, and adaptations for pediatric patients. Each represents a technical barrier that must be addressed before devices can progress beyond early feasibility.
Pediatric mechanical circulatory support presents distinct structural challenges from those in adult care. Patient populations are small, clinical trial sites are limited, and risk tolerance is low. Reimbursement pathways remain uncertain, and development timelines often exceed those of adult devices. As a result, pediatric programs depend heavily on coordinated public funding initiatives.
The NIH PumpKIN program was created to address these barriers by supporting pediatric-specific device development and overseeing funded projects. Dasse served on the PumpKIN Executive Committee, contributing to program-level coordination rather than individual device promotion. His involvement included oversight of the Jarvik 2015 pediatric left ventricular assist system, which progressed from feasibility work toward pivotal readiness.
Within this context, the emphasis shifted from isolated innovation to ecosystem management. Regulatory planning, clinical site engagement, and funding continuity became as critical as device performance itself. Such coordination reflects the realities of pediatric development, in which success depends on alignment across institutions rather than on rapid market entry.
NIH SBIR funding does not operate in isolation. Instead, it functions as part of a broader financing sequence that may include venture capital, strategic partnerships, or eventual acquisition. Within this sequence, SBIR funding is designed to de-risk technical uncertainty rather than replace private investment.
Dasse’s approach to SBIR-supported work has emphasized milestone selection that enables subsequent funding stages. Technical aims are structured to generate data that supports regulatory discussions and informs commercial interests. This requires early attention to quality systems, manufacturing considerations, and human factors, even when products remain years from clinical use.
Such planning reflects an understanding that regulatory and quality frameworks cannot be retrofitted after development milestones are reached. In this sense, SBIR funding serves as a tool for disciplined progression rather than for exploratory research.
The path from grant-funded work to patient use remains largely invisible outside development teams. It begins with feasibility concepts and extends through preclinical validation, failure-mode analysis, and protocol development. Human factors testing, clinical workflow integration, and regulatory engagement follow, often before a device is ever implanted in a patient.
In mechanical circulatory support, many commercial successes rest on years of prior, federally funded development that never received public attention. NIH-supported work frequently establishes the technical and evidentiary foundation on which later programs rely. Dasse’s career illustrates this pattern, with grant-funded efforts contributing to platforms that advanced through multiple organizational and regulatory transitions.
Taken together, Kurt A. Dasse’s NIH-linked activities reflect sustained involvement in translational medical device development rather than episodic participation. His roles as principal investigator, participant in pediatric initiatives such as PumpKIN, and contributor to SBIR-supported programs underscore the importance of funding architecture in shaping which technologies reach patients. In fields where timelines are long and risks are high, such work lays the groundwork for later clinical and commercial milestones.
